Detection of nucleic acids in a biological sample

Inactivating proteinase K with a protease inhibitor like PMSF in the lysis buffer addresses the inefficiencies of high-temperature heating, providing a time-saving, cost-effective, and sensitive nucleic acid detection method for direct PCR.

FR3116065B1Active Publication Date: 2024-11-29INNOVATIVE DIAGNOSTICS GENETICS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2020011611
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-11-12
Publication Date
2024-11-29
Estimated Expiration
2040-11-12

AI Technical Summary

Technical Problem

Conventional methods for inactivating proteinase K in nucleic acid detection require high-temperature heating, which is time-consuming, costly, and can degrade sensitive nucleic acids, leading to loss of sensitivity and metrological uncertainties.

Method used

Inactivation of proteinase K using a protease inhibitor, such as phenylmethylsulfonyl fluoride (PMSF), in the lysis buffer, followed by optional amplification and detection of nucleic acids without prior purification, allowing for direct PCR without the need for heating.

Benefits of technology

This method saves time, reduces costs, and maintains nucleic acid sensitivity by preventing enzyme degradation, offering a more efficient and reliable nucleic acid detection process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000027_0000
    Figure 00000027_0000
  • Figure 00000027_0001
    Figure 00000027_0001
  • Figure 00000027_0002
    Figure 00000027_0002
Patent Text Reader

Abstract

The present invention relates to an in vitro method for releasing, detecting and / or quantifying nucleic acids from a biological sample, comprising the following steps: a) lysis and protein denaturation of the sample by a protease, b) inactivation of the protease by an inhibitor of said protease, c) optionally amplification of the nucleic acids present in the lysate, and d) optionally detection and / or quantification of said nucleic acids.
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Detection of nucleic acids in a biological sample FIELD OF THE INVENTION

[0001] The present invention relates to the field of technologies for detecting nucleic acids in a biological sample, in particular unpurified nucleic acids. STATE OF THE ART

[0002] Nucleic acid detection techniques, with or without amplification, have been developed in many areas of biology.

[0003] In the vast majority of cases, these detection techniques (e.g. hybridization) preceded or not by amplification (e.g. PCR) require a release of the nucleic acids by lysis followed by prior purification of the nucleic acids. This purification step complicates the implementation of the technique. In the past, therefore, there has been interest in the development of direct detection techniques on the biological sample, without prior purification of the nucleic acids. The biological sample is subjected to a simple lysis step allowing the release of the nucleic acids before amplification (optional) and detection and / or quantification of the nucleic acids.

[0004] The release of nucleic acids from a sample can be done by heating at high temperature (e.g. 95-98°C) and / or by chemical lysis (e.g. soda), and / or by enzymatic lysis (e.g. proteinase K).

[0005] Proteinase K is an enzyme of the protease family, widely used in nucleic acid extraction processes in biology and more particularly in molecular biology to release nucleic acids from histones, or from their envelope (viral capsid for example), degrade proteins in the medium that can digest and degrade contaminants in the preparation of nucleic acids (DNase or RNase). Proteinase K degrades proteins by cutting peptide bonds at the level of hydrophobic or aromatic amino acids. It is thus very often used in the preparation of nucleic acids, as a preliminary step to PCR techniques and in particular in the context of direct PCR where it allows the media to be cleaned.

[0006] "Direct PCR" is a technique for amplifying a target sequence (nucleic acids) directly from a sample, without prior purification, required for conventional PCR. This technique is faster than conventional PCR and is used in particular for gene detection and high-throughput screening. The kits Direct PCR assays on samples generally include a lysis buffer specific to the sample being treated and a PCR mix containing enzymes capable of amplifying nucleic acids from an unpurified extract.

[0007] In the case of PCR amplification with release of nucleic acids by lysis then purification of the nucleic acids, proteinase K is eliminated during the purification phase.

[0008] In the case of direct PCR amplification where there is no purification step, proteinase K must be inactivated before the amplification step of these nucleic acids (for example: PCR, RT-PCR, qPCR, RT-qPCR, digital PCR), otherwise it would degrade the enzymes (e.g.: taq polymerase or reverse transcriptase RT) necessary for carrying out the PCR amplification.

[0009] The conventional use of a heating step to inactivate proteinase K is known from the prior art, for example a temperature between 75°C and 100°C for a duration between 10 min and 1 h depending on the type of proteinase K. This is referred to as inactivation by heating. However, this heating step has disadvantages: it requires high-temperature heating equipment, generates a loss of time in the overall process, a loss of sensitivity (fragile nucleic acids, in particular RNAs, can be degraded by excessive heat), and metrological uncertainties when handling a large number of samples.

[0010] There therefore remains a need to develop a new method for inactivating the enzymes present in the lysis buffer of a sample, in particular for inactivating proteinase K, which would also make it possible not to alter, in particular in the case of amplification of the nucleic acids before the detection step, the functionality of the enzymes of the PCR amplification step (e.g.: Taq and RT).

[0011] The Applicant has rightly demonstrated that the use of a protease inactivating compound (e.g. proteinase K) at the sample lysis stage made it possible to meet this need and could in particular be used before enzymatic amplification of the nucleic acids without prior purification (e.g. direct PCR).

[0012] Unexpectedly, the Applicant has in fact shown that it is possible to successfully combine inactivation of proteinase K by an inhibitor compound and enzymatic amplification of the nucleic acids present in the digestate (lysate) after inactivation, without alteration of the enzymes necessary for PCR amplification, and without loss of sensitivity compared to conventional heat inactivation.

[0013] This new method, according to the invention, of inactivating the protease by an inhibitor compound present in the lysis buffer, has numerous advantages compared to the conventional method of heat inactivation:

[0014] - Time saving between 10 min and 1h (no more need for heating); - Reduced cost: no more need for heating equipment; and - No loss of nucleic acid by heating (no loss of sensitivity due to inactivation of proteinase K, unlike the sensitivity of certain RNAs to high temperatures). Statement of the invention

[0015] The invention relates, according to a first aspect, to an in vitro method for releasing, detecting and / or quantifying nucleic acids from a biological sample, comprising the following steps:

[0016] a. lysis and protein denaturation of the sample by a protease, b. inactivation of the protease by an inhibitor of said protease, c. optionally amplification of the nucleic acids present in the lysate, and d. possibly detection and / or quantification of said nucleic acids.

[0017] Another object of the invention is a kit or assembly for implementing an in vitro method for releasing, detecting and / or quantifying nucleic acids from a sample, comprising at least:

[0018] - reagents for the release of nucleic acids by lysis, - a serine protease, preferably proteinase K, - a serine protease inhibitor selected from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF) - optionally a proteinase K substrate, preferably bovine serum albumin; and / or a non-ionic surfactant, and / or an RNase inhibitor, preferably an RNasin, - optionally furthermore a dye, - optionally furthermore reagents for the amplification of said nucleic acids and / or the amplification of housekeeping genes (endogenous control) and / or genes of other control pathogens (exogenous control), and / or optionally furthermore reagents for the detection of said nucleic acids

[0019] The invention also relates to the use of a protease inhibitor, in particular a serine protease inhibitor, preferably selected from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), proteinase K inhibitor, and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF),to inactivate the protease present in a sample lysate intended in particular for amplification by PCR and / or detection and / or quantification of the nucleic acids present in the sample.

[0020] Other characteristics, aims and advantages of the invention will emerge from the following description, which is purely illustrative and not limiting. DETAILED DESCRIPTION OF THE INVENTION

[0021] A first object of the invention is therefore an in vitro method for releasing, detecting and / or quantifying nucleic acids from a biological sample, comprising the following steps:

[0022] a) lysis and protein denaturation of the sample by a protease,

[0023] b) inactivation of the protease by an inhibitor of said protease,

[0024] c) optionally amplification of the nucleic acids present in the lysate, and

[0025] d) optionally detection and / or quantification of nucleic acids.

[0026] According to a first embodiment, the in vitro method of the invention comprises the following steps:

[0027] a. lysis and protein denaturation of the sample by a protease, b. inactivation of the protease by an inhibitor of said protease, and c. optionally detection and / or quantification of the nucleic acids.

[0028] According to another particular and preferred embodiment, the in vitro method of the invention comprises the following steps:

[0029] a) lysis and protein denaturation of the sample by a protease,

[0030] b) inactivation of the protease by an inhibitor of said protease,

[0031] c) amplification of the nucleic acids present in the lysate, and

[0032] d) optionally detection and / or quantification of the amplified nucleic acids.

[0033] The in vitro method according to the invention comprises a step of releasing the nucleic acids from the sample, by simple lysis, without purification.

[0034] According to a particular embodiment, the method of the invention comprises a step c) of amplification by PCR, in particular by direct real-time PCR coupled with hydrolysis probes or coupled with HMR (high resolution melting) analysis or digital or isothermal PCR or any other nucleic acid amplification technique.

[0035] Direct PCR is a technique for amplifying these nucleic acids directly from a sample, without prior purification.

[0036] By 'nucleic acids' is meant in particular the genomic DNAs and RNAs (endogenous) of the subject and / or the DNAs and RNAs of pathogens having infected the subject (exogenous).

[0037] In particular, the nucleic acids detected (optionally amplified) according to the method of the invention are genomic nucleic acids of the subject tested, or nucleic acids of pathogens having infected the subject tested or an environmental medium, in particular DNAs and / or RNAs of bacteria, viruses or parasites. We will subsequently speak of 'target nucleic acids' or 'target sequences', for example position to the 'control sequences', exogenous or endogenous for validation of the method.

[0038] According to a particular embodiment, these are nucleic acids of the subject tested, for example to detect and / or quantify mutations and / or other anomalies correlated with physiological or pathological disorders.

[0039] According to a particular embodiment, these are nucleic acids of pathogens having infected the subject, for example nucleic acids of viruses, bacteria, or parasites, to detect and / or quantify a bacterial or viral load.

[0040] The 'biological sample' according to the invention may in particular be an environmental sample or a sample from an animal or human subject, in particular a sample of bodily fluid, a sample of tissue or organ, or a rag eluate or any other support making it possible to test the environment.

[0041] According to a particular embodiment, the biological sample is a sample from a subject, in particular a sample of bodily fluid chosen from the group consisting of blood and its derivatives (e.g. serum, plasma, leukocyte fractions, in particular serum), urine, saliva, stools, mucous secretions, nasopharyngeal or oropharyngeal swabs, bronchoalveolar fluids, transtracheal aspirations, or a sample of tissue, organ or biopsy, or a wipe eluate.

[0042] The 'test subject' according to the invention may be an animal or a human.

[0043] According to a particular embodiment, the subject is an animal chosen from the group consisting of ruminants, horses, birds, pigs, or pets.

[0044] According to another particular mode, the subject is a human.

[0045] It may be a healthy subject or a subject affected or likely to be affected by a physiological or pathological disorder.

[0046] According to a particular embodiment, it is a subject affected by a physiological or pathological disorder, such as cancer, an inflammatory disease, an infectious disease, an autoimmune disease.

[0047] In particular, the subject tested is a subject infected or likely to be infected by a pathogen, in particular a virus or a bacterium.

[0048] As viruses, and without this list being limiting, we can notably cite co-ronaviruses, such as SARS-COV-2, 229e, OC43, HKU1, NL63 (human coronaviruses), as well as the bovine viral diarrhea virus or African swine fever virus. We can also cite other human respiratory viruses, such as influenza virus, parainfluenza virus, metapneumovirus, respiratory syncytial virus, rhinovirus, Adenovirus, Bocavirus, and Enterovirus.

[0049] As bacteria, and without this list being limiting, we can notably cite human respiratory bacteria such as M.pneumniae, C.pneumoniae, B.pertussis, B.parapertussis, and L. pneumophila.

[0050] a) Step of lysis and protein denaturation of the sample by a protease

[0051] Proteases or peptidases function to cleave proteins or peptides by hydrolyzing their peptide bonds.

[0052] According to a particular and preferred embodiment, a serine protease is used.

[0053] Serine proteases (EC 3.4.21) have a serine residue in their active site which plays an essential role in catalysis.

[0054] Among the serine proteases, we can cite in particular:

[0055] - Trypsin - Chymotrypsin - Proteinase K.

[0056] Thus, according to a particular embodiment of the invention, the protease used in step a) is chosen from the group consisting of serine proteases, in particular proteinase K, trypsin or chymotrypsin, preferably proteinase K.

[0057] According to a particular and preferred embodiment, a proteinase K is used in the step of lysis and denaturation of the sample to be tested.

[0058] Proteinase K is commonly used in molecular biology to digest proteins and remove contaminants from nucleic acid preparation. It can digest cells and extract nucleic acids (DNA or RNA) from mammalian cells or microorganisms.

[0059] The protease will generally be present in the lysis buffer.

[0060] The protease content, in particular proteinase K, will generally range from 0.01 mg / mL to 1 mg / mL, preferably from 0.04 mg / mL to 0.35 mg / mL of reaction medium (lysis buffer).

[0061] A person skilled in the art will adjust the protease content depending on the nature of the sample and volume of the reaction medium.

[0062] The lysis buffer will generally include other ingredients, such as a pH regulating agent, for example a TRIS (tris(hydroxymethyl)aminomethane) buffer, and / or a reducing agent such as B mercaptoethanol or Dithiothreitol (DTT) and / or a nucleobases analogue capable of inhibiting RNases such as vanadyl or vanadyl ribonucleoside complex (VRC).

[0063] Commercial buffer solutions dedicated to the preparation of nucleic acids, in particular for PCR amplification, can be used. Examples include buffer solutions (pH 8.0) marketed by Fisher and Eurobio in particular.

[0064] The step of lysis and protein denaturation of the sample by a protease can be carried out at room temperature or in heat.

[0065] According to a particular embodiment, the lysis step is carried out without heating.

[0066] According to a particular and preferred embodiment, the lysis step is carried out with heating at a temperature ranging from 50°C to 70°C, for a duration ranging from 15 minutes to 1 hour.

[0067] At the end of this step, a lysate is obtained containing the nucleic acids to be amplified (optional) and detected.

[0068] Inactivation of protease, in particular proteinase K, is necessary especially in the case of amplification so that it does not interfere with the enzymes of the PCR amplification reaction.

[0069] b) Step of inactivating the protease by an inhibitor of said protease

[0070] By 'inhibitor' or 'enzyme inhibitor' according to the invention is meant in particular a compound which binds to an enzyme and which reduces its activity. The inhibitor can prevent the substrate from binding to the active site by binding in its place, or cause a deformation of the enzyme making it inactive.

[0071] Binding of an inhibitor can prevent a substrate from binding to the active site of the enzyme and / or the enzyme from catalyzing its reaction. This inhibition can be reversible or irreversible. Irreversible inhibitors bind covalently to the enzyme and modify key amino acid residues necessary for enzymatic activity. In contrast, reversible inhibitors bind non-covalently and different types of inhibition result depending on whether these inhibitors bind the enzyme, the enzyme-substrate complex, or both.

[0072] In the context of the present invention, a protease inhibitor is used.

[0073] The protease inhibitor will generally be present in the stop buffer, but it may be in a separate buffer.

[0074] According to a preferred embodiment, the protease inhibitor is in the stop buffer.

[0075] By 'stop buffer' otherwise called 'inactivation buffer', is meant according to the invention a buffer intended to inactivate the protease, that is to say to prevent its proteolytic activity at the end of the lysis step, and before the nucleic acid amplification step.

[0076] The protease inhibitor may be a chemical compound or a peptide compound.

[0077] According to a particular embodiment, it is a peptide compound.

[0078] As an example, we can cite in particular the tetrapeptidyl chloromethyl ketone otherwise known as Proteinase K inhibitor from Calbiochem. This peptide of formula MeOSuc-Ala-Ala-Pro-Phe-CH2Cl acts as an irreversible inhibitor at the active site of proteinase K.

[0079] According to another particular and preferred embodiment, it is a chemical compound.

[0080] As examples of chemical compounds that can be used in the context of the invention, mention may be made in particular of compounds of the benzenesulfonyl fluoride type, their amino derivatives (e.g. benzenesulfonyl fluoride substituted, in particular on the phenyl ring, by an amino-(Cl-C6) alkyl group) and their salts, dialkylfluorophosphates (e.g. di(Cl-C6) alkylfluorophosphate), and in particular:

[0081] - phenylmethylsulfonyl fluoride (PMSF), also called ben- fluoride zenesulfonyl, (CAS Number 329-98-6), which is a serine protease inhibitor that covalently binds to the active site of the protease, preventing its proteolytic activity; - 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) and its derivatives, particularly in the form of its hydrochloride (CAS Number 30827-99-7), which is an irreversible serine protease inhibitor. It also inhibits trypsin and chymotrypsin; - diisopropylfluorophosphate (DFP);

[0082] preferably PMSF or AEBSF, more preferably PMSF.

[0083] Thus, according to a particular embodiment of the invention, the protease inhibitor used in step b) of the process of the invention is a serine protease inhibitor chosen from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF).

[0084] As an example, the PMSF from Merck or the AEBSF from Merck are used.

[0085] The concentration of protease inhibitor used in the method of the invention may range from 0.1mM to 30mM, in particular from 0.5mM to 20mM, and in particular from 0.5mM to 15mM.

[0086] A person skilled in the art will know how to adjust the concentration of protease inhibitor according to its nature and the nature and concentration of the target protease.

[0087] According to a particular embodiment, the protease is a proteinase K and the protease inhibitor is chosen from PMSF and AEBSF, preferably PMSF.

[0088] According to a particular embodiment, for a proteinase K concentration of 0.35 mg / mL, a concentration ranging from 20 mM to 60 mM, preferably from 30 mM to 50 mM of PMSF and ranging from 6.5 mg / mL to 13 mg / mL of AEBSF will advantageously be used.

[0089] This step of chemical inactivation of the protease is generally carried out at room temperature. Decoy protein (optional)

[0090] According to a particular embodiment of the invention, the method of the invention further comprises bringing the lysate into contact with a decoy protein.

[0091] By 'decoy protein' according to the invention is meant a substrate protein of the protease, making it possible to eliminate the residual proteolytic activity of the protease in the reaction medium.

[0092] As substrate for the protease, in particular for proteinase K, any protein which is not a PCR inhibitor can be used, in particular plasma proteins, in particular albumin, preferably bovine serum albumin (BSA for Bovine Serum Albumin), or collagens, for example porcine collagen.

[0093] Thus, according to a particular embodiment of the invention, the inactivation step b) further comprises bringing the lysate into contact with a substrate of said protease, in particular a plasma protein or a collagen, preferably a plasma protein such as albumin, more preferably bovine serum albumin (BSA).

[0094] Preferably, a plasma protein is used, more preferably an albumin such as BSA.

[0095] The decoy protein concentration will generally range from 4 mg / mL to 20 mg / mL, preferably from 6 mg / mL to 10 mg / mL of reaction medium.

[0096] Those skilled in the art will know how to adjust the concentration of decoy protein as a function of the concentration of the target protease.

[0097] The decoy protein may be present in the stop buffer (inactivation buffer) or in a separate buffer, added before or after the stop buffer.

[0098] According to a preferred embodiment, the decoy protein is in the stop buffer. Surfactant (optional)

[0099] According to a particular embodiment of the invention, the method of the invention further comprises bringing the lysate into contact with a surfactant chosen from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, zwitterionic surfactants, and mixtures thereof.

[0100] This surfactant will facilitate the release of nucleic acids, before the amplification step, thus improving the sensitivity of the lysis process.

[0101] According to a particular embodiment, the surfactant is a non-ionic surfactant.

[0102] As non-ionic surfactant, mention may be made in particular of octylphenoxypolyethoxyethanol (Triton™ X100), nonylphenol ethoxylate (Tergitol™ type NP-40) or polysorbates, in particular polysorbate 20 otherwise known as Polyethylene glycol sorbitan monolaurate (CAS Number: 9005-64-5). Mention may be made, for example, of polysorbate 20 marketed under the name TWEEN® 20 by the company Merck.

[0103] Thus, according to a particular embodiment of the invention, the inactivation step b) of the method of the invention further comprises bringing the lysate into contact with a non-ionic surfactant, in particular an octylphenoxypolyethoxyethanol (Triton™ X 100), a nonylphenol ethoxylate (Tergitol™ type NP-40) or a polysorbate, such as polysorbate 20.

[0104] The content of surfactant used in the process according to the invention will generally range from 0.1% to 20% by weight relative to the weight of the reaction medium.

[0105] Those skilled in the art will know how to adapt the content of surfactant according to its nature and the target sequence.

[0106] For example, for a polysorbate 20, a content of 5% to 20% in in particular from 8% to 15% by weight relative to the weight of the reaction medium.

[0107] For an octylphenoxypolyethoxyethanol (Triton™ X 100), a content of 1% to 10%, in particular 2% to 5% by weight relative to the weight of the reaction medium, may be used.

[0108] For a nonylphenol ethoxylate (Tergitol™ type NP-40), a content of 0.1% to 5%, in particular 0.2 to 1% by weight relative to the weight of the reaction medium, may be used.

[0109] The surfactant may be present in the stop buffer or in a separate buffer, used before, with, or after the stop buffer.

[0110] Preferably, the surfactant is in the stop buffer. RNA protectors (optional)

[0111] According to a particular embodiment of the invention, the method of the invention further comprises bringing the lysate into contact with an RNA protector.

[0112] By 'RNA protector' is meant an agent that prevents the degradation of RNAs. Examples include RNase inhibitors, particularly RNasin.

[0113] The content of RNasin used in the process according to the invention will generally range from 0.05U / pl to 25U / pl by weight relative to the weight of the reaction medium.

[0114] The RNA protecting agent may be present in the stop buffer or in a separate buffer, used before, with, or after the stop buffer.

[0115] Preferably, the RNA protecting agent is in the stop buffer.

[0116] According to a particular embodiment, the inactivation step b) further comprises bringing the lysate into contact with:

[0117] - a substrate of said protease, in particular a plasma protein or a collagen, preferably a plasma protein such as albumin, more preferably bovine serum albumin (BSA), and / or

[0118] - a surfactant selected from the group consisting of non-surfactants ionic, anionic, cationic, zwitterionic, and mixtures thereof, in particular a non-ionic surfactant, in particular an octylphenoxypolyethoxyethanol, a nonylphenol ethoxylate, or a polysorbate such as polysorbate 20, and / or

[0119] - an RNase inhibitor, in particular RNasin.

[0120] Thus, the stop buffer according to the invention advantageously comprises:

[0121] - a protease inhibitor as described above, to inactivate in particular proteinase K, - a decoy protein as described above, to eliminate the residual proteolytic activity of the protease in the reaction medium, - a surfactant as described above, to facilitate the ultimate release of the nucleic acids from their protein environment, and - an RNase inhibitor as described above, in particular an RNasin, and - advantageously in addition a dye, in particular a dye which is not a PCR inhibitor

[0122] The presence of a colorant makes it possible to facilitate the implementation of the method of the invention.

[0123] According to a particular and preferred embodiment of the invention, the in vitro method for releasing, detecting and / or quantifying nucleic acids from a sample of a subject comprises the following steps:

[0124] a. lysis and protein denaturation of a sample chosen from the group consisting of a salivary sample, an oropharyngeal or nasopharyngeal sample, with a proteinase K, in particular carried out at a temperature of 50 to 60°C for 15 to 60 minutes, b. inactivation of proteinase K by addition of phenylmethylsulfonyl fluoride (PMSF), advantageously in addition to a bovine serum albumin (BSA), advantageously in addition to a non-ionic surfactant, and advantageously in addition to an RNasin, c. optionally amplification of the nucleic acids present in the lysate, and d. possibly detection and / or quantification of the nucleic acids.

[0125] c) Amplification step (optional) of the nucleic acids present in the lysate

[0126] This step of amplification of the target sequences and the control sequences is carried out by well-known PCR methods (e.g. qPCR, RT-PCR, digital PCR, isothermal PCR, etc.), in the presence of enzymes (e.g. Taq polymerase and RT-transcriptase).

[0127] By 'target sequences' or 'target nucleic acids' is meant genomic nucleic acids of the test subject, or nucleic acids of pathogens having infected the test subject, in particular DNAs and / or RNAs of bacteria, viruses, parasites or fungi.

[0128] According to a particular embodiment, these are nucleic acids of the subject tested, for example to detect and / or quantify mutations and / or other anomalies correlated with physiological or pathological disorders.

[0129] According to a particular embodiment, these are nucleic acids of pathogens having infected the subject, for example nucleic acids of viruses, bacteria or parasites, to detect and / or quantify a bacterial or viral load.

[0130] The amplification step may require the use of control sequences, endogenous and / or exogenous.

[0131] By 'control sequences' we mean in particular:

[0132] - endogenous sequences such as housekeeping genes, characterized by their intrinsic presence in all cells of the sample in a constitutive manner. Examples include genes coding for proteins highly conserved such as the beta 2 microglobulin protein or the actin protein and in particular the beta form (we speak of 'endogenous control') and / or - exogenous sequences such as genes from pathogens other than the one sought but of a nature very close to the target; examples include mengovirus, also known as Columbia SK virus, mouse El-berfield virus and encephalomyocarditis virus, a virus non-pathogenic to humans serving as an exogenous control for RNA viral targets; for DNA bacterial targets, examples include the sequence of a non-pathogenic microorganism such as Mycobacterium smegmatis or E.coli (this is referred to as 'exogenous control').

[0133] Endogenous controls allow the presence and integrity of the sample to be validated during all phases of the analytical process. They allow the presence of cells to be validated, the correct handling and release of nucleic acids from the sample and the absence of PCR inhibitors to be verified.

[0134] Exogenous controls are added to the sample during the analytical process and allow validation of the efficiency and proper conduct of the nucleic acid release and amplification phases.

[0135] Those skilled in the art will know how to adapt the method according to the invention (presence or absence of endogenous and / or exogenous control sequences) depending on the target and the purpose (detection and / or quantification method, diagnostic method, etc.).

[0136] According to a particular embodiment, the method of the invention allows co-amplification, in particular in the same well, of the target sequences (e.g.: target genomic sequence of the subject or sequence of a pathogen likely to have infected said subject), and of control sequences.

[0137] Thus, the method according to the invention, preferably for direct PCR, comprises:

[0138] - a system for amplifying the target sequences comprising sense primers and antisense amplification of the above-described 'target sequences' and specific probes, advantageously labeled with fluorophores, for detecting the amplified target sequences; and

[0139] - possibly a system for amplification of endogenous control sequences (housekeeping genes) and exogenous (sequences of another pathogen) comprising sense and antisense primers for amplifying said control sequences and specific probes, advantageously labeled with fluorophores, for detecting said amplified control sequences.

[0140] Those skilled in the art will know how to choose the sense and antisense primers specific to the target sequences to be amplified, as well as the specific probes adapted to the detection of the amplified target and control sequences.

[0141] According to a particular embodiment, the method comprises:

[0142] - a system for amplifying viral sequences of avian coronavirus (Infectious bronchitis virus, IBV) comprising sense and antisense primers for amplifying said viral sequences and specific probes, advantageously labeled with fluorophores, for detecting the amplified target sequences; and

[0143] - possibly a system for amplifying exogenous control sequences (e.g.: mengovirus sequences) comprising sense and antisense primers for amplifying said control sequences and specific probes, advantageously labeled with fluorophores, for detecting said amplified control sequences.

[0144] The kit for implementing such an IBV detection method may further comprise a reagent comprising the inactivated and calibrated exogenous virus (mengovirus) to be added constantly to each sample before the start of the method.

[0145] Commercially available reagents, primers and probes suitable for PCR amplification can be used, following the supplier's recommendations.

[0146] d) Step of detection and / or quantification of amplified or non-amplified nucleic acids

[0147] This step of detection and / or quantification of the amplified or non-amplified target sequences is carried out by methods well known to those skilled in the art.

[0148] For direct detection (without amplification), hybridization methods well known to those skilled in the art (e.g. Northern blot, dotblot, etc.) can be cited.

[0149] For detection with prior amplification (e.g. Taqman amplification, isothermal amplification, digital amplification), fluorescence detection methods well known to those skilled in the art can be cited.

[0150] Kit

[0151] The present invention also relates to a kit or assembly for implementing a method according to the invention, comprising at least:

[0152] - reagents for the release of nucleic acids by lysis; - a serine protease, preferably proteinase K, - a serine protease inhibitor selected from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF), - optionally further a proteinase K substrate, preferably a bovine serum albumin (BSA) and / or a non-ionic surfactant, and / or an RNase inhibitor, preferably an RNasin, - optionally in addition a colorant, - possibly reagents for the amplification of said nucleic acids and / or the amplification of housekeeping genes (endogenous control) and / or genes of other control pathogens (exogenous control), and / or - possibly reagents for the detection of said nucleic acids.

[0153] Serine protease is generally present in the lysis buffer.

[0154] The serine protease inhibitor is generally present in the stop buffer.

[0155] The proteinase K substrate and the nonionic surfactant may be present in the stop buffer or in a separate buffer.

[0156] Thus, according to a particular embodiment, the kit or assembly according to the invention comprises at least:

[0157] - A lysis buffer comprising proteinase K, - A stop buffer comprising: • a serine protease inhibitor preferably selected from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF) • a proteinase K substrate, preferably bovine serum albumin (BSA) • a non-ionic surfactant, preferably an octylphenoxypolyethoxyethanol, a nonylphenol ethoxylate, or a polysorbate such as polysorbate 20, • optionally in addition an RNase inhibitor, preferably an RNasin and • possibly also a colorant.

[0158] According to a particular embodiment, the kit or assembly according to the invention comprises:

[0159] - A lysis buffer comprising a proteinase K (from 0.04 mg / mL to 0.08 mg / mL) - A stop buffer comprising PMSF (20mM to 40mM) + BSA (3.25mg / mL to 6.5mg / mL) + Commercial buffer pH 8.0 + a non-ionic surfactant of the Tween® 20 type (5% to 10%) or alternatively Triton™ X-100 (1.25% to 2.5%) or Tergitol™ of the NP-40 type (0.25% to 0.5%), optionally an RNasin, and advantageously in addition a dye.

[0160] A person skilled in the art will know how to adjust the reagent contents, in particular the contents of serine protease, serine protease inhibitor, decoy protein and non-ionic surfactant, depending on the nature of the sample and the nucleic acids to be detected (genomic, pathogenic).

[0161] The invention also relates to the use of a protease inhibitor, in particular a serine protease inhibitor, preferably selected from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), proteinase K inhibitor, and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF), for inactivating the protease present in a sample lysate intended in particular for amplification and / or detection and / or quantification of the nucleic acids present in the sample. FIGURES

[0162] [Fig. 1] qPCR results of the PK inhibition test by heating and alternatively by a protease inhibitor (PMSF).

[0163] [Fig.2] Evaluation of a PCR amplification (fluorescence measurement) with and without inac PK stimulation.

[0164] [Fig.3] Evaluation of a PCR amplification (fluorescence measurement) with or without PK, on a nasopharyngeal swab sample positive for SARS-CoV-2.

[0165] [Fig.4] Evaluation of a PCR amplification (fluorescence measurement) with inactivation by heating or chemical inactivation of PK, on ​​a nasopharyngeal swab sample positive for SARS-Cov-2.

[0166] [Fig.5] qPCR results of the PK inhibition test with PMSF in the presence or absence of BSA.

[0167] [Fig.6] qPCR results of PK inhibition test with PMSF, BSA and in the presence or not Tween 20.

[0168] [Fig.7] qPCR results of the PK inhibition test with PMSF in the presence of mix Taq and RT enzyme reactions.

[0169] [Fig.8] qPCR results of PK inhibition assay with AEBSF.

[0170] The invention will be illustrated in the following non-limiting examples.

[0171] EXAMPLES

[0172] Example 1: Effect of a proteinase K (PK) inhibitor compared to conventional PK inhibition by heating

[0173] The technical effect of the efficiency of proteinase K (PK) inactivation by an inhibitor compound compared to conventional inactivation by heating was demonstrated on a purified RNA model of avian coronavirus (Infectious bronchitis virus, IBV). The objective here was to demonstrate that the PK inhibitor indeed allowed PK to be inactivated as well as conventional inactivation by heating at 95°C for 10 minutes.

[0174] For this we carried out a PCR amplification of the RNA of the purified IBV virus, according to different comparative conditions:

[0175] - without heating (Witness),

[0176] - after heating at 95°C for 10 minutes (heating effect on RNA detection),

[0177] - after heating 95°C for 10 min in the presence of PK (impact of heating on PK inactivation),

[0178] - with the addition of 10mM or 16mM of a PK inhibitor, Phenylmethyl Fluoride- sulfonyl (PMSF), in the presence of PK (impact of the inhibitor on PK inactivation).

[0179] The results are presented in [Fig.l] and in Table 1 below:

[0180] [Tables 1] Cq Method RNA alone 24.82 RNA alone 95°C 10' 25.10 RNA + PK 95°C 28.71 RNA + PK + PMSF 10 mM 28.61 RNA + PK + PMSF 10 mM 26.55

[0181] The Cq (threshold cycle) corresponds to the intersection between an amplification curve and a threshold line. It corresponds to a relative measure of the concentration of the target in the PCR reaction.

[0182] “Cq” corresponds to a Nucleic Acid detection sensitivity value. Thus, the earlier the Cq, the more material there is (Nucleic Acid at the start) and therefore the greater the load of the pathogenic agent in the patient tested. The Cq will therefore be in molecular biology one of the main data to establish a relative quantification of the "infectious load".

[0183] These results show that heating the RNA for 10 min does not induce loss of Cq, therefore no loss of material.

[0184] On the other hand, heating in the presence of PK induces a shift in the detection of RNA reflecting a loss of material; PK therefore does not appear to be completely inactivated by heating at 95°C for 10 min.

[0185] The addition of a PK inhibitor (PMSF) at 10 mM allows RNA detection equivalent to conventional heating inactivation. This indicates that the presence of PMSF at this concentration is sufficient to inactivate PK, as well as conventional heating inactivation. Furthermore, when the PMSF concentration is increased, it is observed that the detection becomes even closer to the control alone, indicating that PK is inactivated even better than conventional heating inactivation.

[0186] The use of an inhibitor is therefore advantageous, in a condition of lysis and protein denaturation of a sample with a protease (e.g.: PK), compared to conventional inactivation by heating.

[0187] Example 2: Necessary inactivation of PK before PCR amplification

[0188] Example 2-1: Amplification and detection of an extracted IBV viral RNA

[0189] The interest of inactivating PK before use in PCR has been re-demonstrated here.

[0190] To do this, we used an already extracted IBV viral RNA, and added PK according to 3 operating conditions: PK inactivated by heating (comparative), or non-inactivated PK (control) or PK in the presence of 10mM PMSF (invention). Then we amplified this viral RNA by RT-qPCR.

[0191] The first sample contains a defined quantity of extracted IBV RNA to which PK has been added at a concentration of 0.3 mg / mL, inactivated by heating at 95°C for 10 minutes (comparative). For the defined quantity of IBV RNA, a dilution of 1 / 3000 is used, which results in a Cq of 24-25.

[0192] The second sample contains the same concentration of extracted IBV RNA, but the PK (same concentration) is not inactivated (control).

[0193] The third sample still contains the same concentration of RNA and PK but this time, the PK is inactivated by a stop solution containing PMSF alone 10 mM (invention).

[0194] 5 pL of each sample is added to the 15 pL of reaction mix (ID Gene™ In- fectious Bronchitis Duplex from IDvet) and RNA amplification by RT-qPCR is carried out according to the supplier's recommendations:

[0195] ID Gene™ Infectious Bronchitis Duplex from IDvet

[0196] Amplification Program:

[0197] [Tables2] 10 min at 50°C 2 min at 95°C 10 sec at 95°C 40 steps 30 sec at 60°C

[0198] *fluorescence acquisition. The results are shown in [Fig.2].

[0199] It is observed that no amplification is detected in the case where Proteinase K is not inactivated (control), whereas RNA is well detected in the other two cases (presence of a characteristic curve). The results clearly show us that in the absence of inactivation (by an inhibitory compound or by heating), Proteinase K cannot under any circumstances be used with a PCR technique because it degrades the enzymes necessary for carrying out the reaction.

[0200] Example 2-2: amplification and detection of a SARS-Cov-2 viral RNA

[0201] We used supernatants from nasopharyngeal swabs tested positive for SARS-CoV-2 coronavirus and showed the benefit of chemical inactivation of PK by compared to inactivation by heating.

[0202] Initially, we tested comparative heating or PK treatment conditions:

[0203] - Simple heating without proteinase K (PK) at 56°C 30min - Simple heating without proteinase K (PK) at 95°C for 10 min; - Addition of a lysis buffer with PK (0.04mg / mL) then incubation for 30min at 56°C - Addition of a lysis buffer with PK then incubation for 30 min at 56°C at room temperature.

[0204] Then we amplified this viral RNA by RT-qPCR.

[0205] For the defined quantity of SARS-Cov-2 viral RNA, a supernatant sample of nasopharyngeal swabs from a patient previously tested by purification and amplification and found positive at a Cq of 18-19 is used.

[0206] 5 pL of each sample is added to the 8 pL of reaction mix and the amplification RNA by RT-qPCR is carried out according to the supplier's recommendations (see amplification program below).

[0207] For each amplification reaction, 0.4 pM of each primer and 0.2 pM of probe are used. The Master Mix and Reverse Transcriptase (RT) are added according to the concentrations recommended by the supplier: Capital™ qRT-PCR Probe Mix 4X from Biotechrabbit (Ref: BR0502003):

[0208] - for 'without PK' conditions: direct sampling of 5pl after heating; - for 'with PK' conditions: sample 20pl after heating with PK and addition of 5pl of stop buffer then collection of 5pl and addition of 8pl of PCR mix.

[0209] Amplification Program:

[0210] [Tables3] 10 min at 50°C 2 min at 95°C 10 sec at 95°C 40 steps 30 sec at 60°C

[0211] *fluorescence acquisition (fluorophore FAM = fluorescein).

[0212] The results are presented in the following Table 4 and in [Fig.3].

[0213] [Tables4] Method Cq (FAM) Heating 56°C 30min without PK 23.1 Heating 56°C 30min with PK 19.9 Heating 95°C 10 min without PK 22.0 Incubation TA 30 min with PK 19.5

[0214] We observe that the addition of PK presents a real interest in producing earlier signals and therefore gaining in sensitivity compared to simple heating.

[0215] In a second step, conditions for inactivating PK by heating or by treatment with a chemical inhibitor according to the invention (PMSF 4mM) were comparatively tested, before the PCR amplification step using the protocol described above.

[0216] The results are presented in the following Table 5 and in [Fig.4].

[0217] [Tables5] Cq Method (FAM) Heating 56°C 30min with PK + chemical block 19.9 Heating 56°C 30min with PK + heat block 23.8 Incubation TA 30 min with PK + chemical block 19.5 Incubation TA 30 min with PK + heat block 22.7

[0218] It is observed that the use of chemical blocking makes it possible to detect the signal earlier and therefore to be more sensitive in the detection of samples.

[0219] Example 3: Effect of adding a PK decoy protein to the PK inhibitor

[0220] The objective here was to demonstrate that the addition of a “decoy” protein such as Bovine serum albumin (BSA) helps inactivate residual PK activity, thus reducing the amount of PMSF needed to completely inactivate PK activity.

[0221] For this we amplified by PCR the purified IBV RNA alone (expected detection control), the purified RNA with 10mM or 16mM PMSF in the presence of PK (control inactivation by an inhibitory compound) and the purified RNA with 10mM or 16mM PMSF in the presence of PK + BSA at 4mg / ml or 8mg / ml.

[0222] The results are presented in [Fig.4] and the following Table 6:

[0223] [Tableauxô] PMSF 10mM Cq Cq PMSF 16 mM RNA alone 24.82 24.82 RNA alone RNA alone 95°C 10' 25.1 25.1 RNA alone 95°C 10' RNA + PK PMSF 10mM 28.61 26.55 RNA + PK PMSF 16mM RNA + PK PMSF 10mM+ BSA 4mg / mL 25.41 25.38- 26.18 RNA + PK PMSF 16mM+ BSA 4mg / mL RNA + PK PMSF 10mM+ BSA 8 mg / mL 25.01 25.09 RNA + PK PMSF 16mM+ BSA 8 mg / mL

[0224] In the presence of 10 mM PMSF with PK at 0.3 mg / ml, the signal is not restored to 100% (later Cq) which means that PK is not completely inactivated. When the amount of PMSF is increased, it is observed that the Cq delay becomes weaker, which indicates that the increase in PMSF does indeed allow better inactivation of PK.

[0225] But too high concentrations of PMSF can interfere with the PCR enzymes and harm the PCR amplification step. The addition of a decoy protein (here BSA) makes it possible to restore the signal detection at a Cq equivalent to the control (RNA alone), which indicates that it makes it possible to eliminate the residual activities of the PK, thus protecting the PCR enzymes. The more BSA is added, the greater the signal restoration seems to be.

[0226] These results show that it may be advantageous to combine a decoy protein such as BSA with a PK inhibitor such as PMSF, to achieve total inactivation of PK, at lower PMSF levels.

[0227] Example 4: Effect of adding a non-ionic surfactant to the PK inhibitor

[0228] The effect of adding a non-ionic surfactant such as polysorbate-20 (Tween 20) to the stop buffer was evaluated in this example. The objective was to show that it allowed for better release of viral RNA and thus improve the lysis process, before the amplification step.

[0229] A dry swab of 25 μl of nasopharyngeal swab supernatant positive for sars-cov2 was prepared and then taken up in the lysis buffer (TE + PK 0.08 mg / mL) and then heated at 56°C for 30 min. A volume of 20 μl of the lysate thus obtained was inactivated with 5 μl of a stop buffer containing Tween 20 (PMSF 40 mM / BSA 6.5 mg / mL / Tween20 10%) or a stop buffer of similar composition but without Tween 20 (PMSF 40 mM / BSA 6.5 mg / mL).

[0230] The results are shown in [Fig.5].

[0231] It is observed that by adding Tween 20 to the stop buffer, there is a gain in sensitivity resulting in the obtaining of an earlier Cq in PCR.

[0232] These results show that the addition of a non-ionic surfactant to the stop buffer promotes the release of viral RNA not yet extracted, and thus improves the sensitivity of the lysis process.

[0233] Example 5: Use of PMSF-inactivated PK with different Taq and RT PCR enzymes

[0234] Different Taq and RT (with their respective buffers) were tested. We amplified the extracted viral RNA alone (control) or in the presence of different doses of PK (0.12mg / mL and 0.24mg / mL) and constant doses of PMSF inhibitor (8mM) and BSA (1.3mg / mL).

[0235] For each amplification reaction, 0.4 pM of each of the primers and 0.2 pM of probe are used. The Master Mix and Reverse Transcriptase (RT) are added according to the concentrations recommended by the supplier(s).

[0236] In particular, the following Taq and RT mixes were tested:

[0237] Mix A: Capital™ qRT-PCR Probe Mix 4X from Biotechrabbit (Ref: BR0502003)

[0238] And Mix B: Lyoready 1-Step RT-qPCR Mix 2X from Meridian-Bioline (Ref: MDX024)

[0239] The results are shown in [Fig.6].

[0240] The PK is indeed inactivated since the signal observed with mixes A and B is equivalent to the signal without PK.

[0241] These results show that the use of a PMSF-inactivated PK does not alter PCR amplification reactions in the presence of Taq and RT enzymes.

[0242] Those skilled in the art will know how to adjust the operating conditions (Taq, RT and inactivated PK contents) depending on the nature of the Taq and RT mixes sold and the suppliers' recommendations.

[0243] Example 6: Effect of AEBSF on PK inactivation

[0244] PK is used at a typical concentration of 0.35 mg / mL.

[0245] Different concentrations of AEBSF were tested and a concentration of 1 mg / mL was chosen to carry out PCR amplification in the presence of extracted RNA (IBV viral RNA) to identify its possible inhibitory effect on the Taq and RT enzymes of PCR amplification.

[0246] The results are illustrated in Table 7 below and in [Fig.7].

[0247] [Tables?] Cq method RNA alone 24.93 RNA + PMF BSA 24.82 RNA + AEBSF 1 mg / mL 27.23

[0248] 10 mM of PMSF corresponds to 1.742 mg / mL based on the following calculation:

[0249] Molar mass PMSF = 174.2 g / mol

[0250] 0.01 mol / L * 174.2 g / mol = 1.742 g / L of PMSF = 1.742 mg / mL

[0251] These results show that AEBSF, like PMSF, is another effective PK inhibitor compatible with PCR amplification (does not alter PCR enzymes).

[0252] Example 7: Implementation of a method according to the invention 7-1: Amplification and detection of IBV viral RNA

[0253] In this example, an attempt was made to detect avian coronavirus (Infectious bronchitis virus, IBV) nucleic acids in a nasopharyngeal swab. The method consisted of:

[0254] 1 / Collect the swab supernatant to be tested and add the buffer inside. lysis including proteinase K (0.08 mg / mL)

[0255] 3 / Vortex 30s

[0256] 4 / Centrifuge for a few seconds to bring the entire sample to the bottom of the tube

[0257] 5 / Heat the sample for 30 min at 56°C

[0258] 6 / Vortexer

[0259] 7 / Centrifuge for a few seconds to bring the entire sample to the bottom of the tube

[0260] 8 / ​​Homogenize the stop solution (stop buffer comprising 40mM PMSF, 6.5mg / mL BSA and 10% Tween 20 or 2.5% Triton X-100 or 0.5% Tergitol™ type NP-40) gently by suction

[0261] 9 / In a pre-dilution plate (or in eppendorf tubes), distribute 5pl of stop buffer per lysed sample well

[0262] 10 / Take 20pl of the lysate supernatant (after heating) and mix them thoroughly cate by suction / discharge at 5pl of stopping solution.

[0263] 11 / In a PCR plate or strips, distribute the reaction mix according to the supplier's amplification protocol (ID Gene™ Infectious Bronchitis Duplex from IDvet)

[0264] 12 / Add 5pl of the inactivated lysate

[0265] 13 / Carry out the PCR following the supplier's recommendations.

[0266] 7-2: Amplification and detection of SARS-Cov-2 viral RNA

[0267] In this example, an attempt was made to detect human coronavirus (SARS-Cov-2) nucleic acids in a nasopharyngeal swab. The method consisted of:

[0268] 1 / Collect the swab supernatant to be tested and add the buffer inside. lysis including proteinase K (0.04 mg / ml in the presence of the sample)

[0269] 3 / Vortex 30s

[0270] 4 / Centrifuge for a few seconds to bring the entire sample to the bottom of the tube

[0271] 5 / Heat the sample for 30 min at 56°C

[0272] 6 / Vortexer

[0273] 7 / Centrifuge for a few seconds to bring the entire sample to the bottom of the tube

[0274] 8 / Homogenize the stop solution (stop buffer comprising 20mM PMSF, 3.25mg / mL of BSA and 5% of Tween 20 or 1.25% of Triton X-100 or 0.25% of Tergitol™ type NP-40) gently by suction,

[0275] 9 / In a pre-dilution plate (or in eppendorf tubes), distribute 5pl of stop buffer per lysed sample well,

[0276] 10 / Take 20pl of the lysate supernatant (after heating) and mix them thoroughly suction / discharge catelement with 5pl of stopping solution

[0277] 11 / In a PCR plate or strips, distribute 8pl of a mix composed of 0.4 pM of each primer and 0.2 pM of probe. The Master Mix and Reverse Transcriptase (RT) are added according to the concentrations recommended by the supplier: Capital™ qRT-PCR Probe Mix 4X from Biotechrabbit (Ref: BR0502003)

[0278] 12 / Add 5pl of the inactivated lysate,

[0279] 13 / Carry out the PCR following the supplier's recommendations.

Claims

Claims

1. An in vitro method for releasing, detecting and / or quantifying nucleic acids from a biological sample, comprising the following steps: a. lysis and protein denaturation of the sample by a protease, b. inactivation of the protease by an inhibitor of said protease without heating, c. optionally amplification of the nucleic acids present in the lysate, and d. optionally detection and / or quantification of said nucleic acids.

2. Method according to claim 1, characterized in that it comprises a step c) of amplification of said nucleic acids by PCR, in particular by direct PCR or by digital or isothermal PCR.

3. Method according to claim 1 or claim 2, characterized in that the protease used in step a) of lysis is chosen from the group consisting of serine proteases, in particular proteinase K, trypsin or chymotrypsin, preferably proteinase K.

4. Method according to any one of claims 1 to 3, characterized in that the protease inhibitor used in the inactivation step b) is a serine protease inhibitor chosen from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF).

5. Method according to any one of claims 1 to 4, characterized in that the inactivation step b) further comprises bringing the lysate into contact with: - a substrate of said protease, in particular a plasma protein or a collagen, preferably a plasma protein such as albumin, more preferably bovine serum albumin (BSA), and / or - a surfactant chosen from the group consisting of non-ionic, anionic, cationic, zwitterionic surfactants, and mixtures thereof, in particular a non-ionic surfactant, in particular a octylphenoxypolyethoxyethanol, a nonylphenol ethoxylate, or a polysorbate such as polysorbate 20, and / or - an RNase inhibitor, in particular RNasin.

6. Method according to any one of claims 1 to 5, characterized in that the biological sample is a sample from a subject, in particular from an animal or a human, in particular a sample of bodily fluid chosen from the group consisting of blood and its derivatives, urine, saliva, stools, mucous secretions, nasopharyngeal or oropharyngeal swabs, bronchoalveolar fluids, transtracheal aspirations or a sample of tissue, organ or biopsy, or a wipe eluate.

7. Method according to any one of claims 1 to 6, characterized in that the nucleic acids detected from the lysate are genomic nucleic acids of the subject tested, or nucleic acids of pathogens having infected the subject tested, in particular DNAs and / or RNAs of bacteria, viruses, parasites or fungi.

8. Method according to any one of claims 1 to 7, characterized in that it comprises the following steps: a) lysis and protein denaturation of a sample chosen from the group consisting of a salivary sample, an oropharyngeal or nasopharyngeal sample, with a proteinase K, in particular carried out at a temperature of 50 to 60°C for 15 to 60 minutes, b) inactivation of the proteinase K by addition of phenylmethylsulfonyl fluoride (PMSF), advantageously in addition to a bovine serum albumin (BSA), advantageously in addition to a non-ionic surfactant, and advantageously in addition to an RNasin, c) optionally amplification of the nucleic acids present in the lysate, and d) optionally detection and / or quantification of the nucleic acids.

9. Kit or assembly for implementing a method according to any one of claims 1 to 8, characterized in that it comprises at least: - reagents for the release of nucleic acids by lysis, - a serine protease, preferably proteinase K; - a serine protease inhibitor preferably chosen from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF); - a proteinase K substrate, preferably bovine serum albumin (BSA), - optionally a dye, - optionally in addition reagents for the amplification of said nucleic acids and optionally the amplification of housekeeping genes (endogenous control) and / or genes of other control pathogens (exogenous control) and / or - possibly in addition reagents for the detection of said nucleic acids.

10. Kit or assembly according to claim 9, characterized in that it comprises at least: - A lysis buffer comprising proteinase K, - A stop buffer comprising: • a serine protease inhibitor preferably selected from the group consisting of phenylmethylsulfonyl fluoride (PMSF), aminoethylbenzenesulfonyl fluoride hydrochloride (AEBSF), and mixtures thereof, preferably phenylmethylsulfonyl fluoride (PMSF) • a proteinase K substrate, preferably bovine serum albumin (BSA) • a non-ionic surfactant, preferably an oc-tylphenoxypolyethoxyethanol, a nonylphenol ethoxylate, or a polysorbate such as polysorbate 20, • optionally in addition an RNase inhibitor, preferably an RNasin and • possibly also a colorant.